Evidence map›Paper›PMID 33378334›Full record

ArticlePloS one2020

Optically activated, customizable, excitable cells.

Merrilee Thomas, Thomas E Hughes

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. The network of cardiac KNaunyn-Schmiedeberg's archives of pharmacology · 2024
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Merrilee ThomasDepartment of Neuroscience and Cell Biology, Montana State University, Bozeman, Montana, United States of America.ORCID 0000-0002-3430-0912
Thomas E HughesDepartment of Neuroscience and Cell Biology, Montana State University, Bozeman, Montana, United States of America.
Montana State University · US

Funding

New approaches for better protein voltage sensorsU01NS099691 · NINDS · YALE UNIVERSITY · PI COHEN, LAWRENCE B · 2016 to 2018
$2.1M
NINDS NIH HHS U01 NS099691
6 · The paper itself

Abstract

Genetically encoded fluorescent biosensors are powerful tools for studying complex signaling in the nervous system, and now both Ca2+ and voltage sensors are available to study the signaling behavior of entire neural circuits. There is a pressing need for improved sensors, but improving them is challenging because testing them involves a low throughput, labor-intensive processes. Our goal was to create synthetic, excitable cells that can be activated with brief pulses of blue light and serve as a medium throughput platform for screening the next generation of sensors. In this live cell system, blue light activates an adenylyl cyclase enzyme (bPAC) that increases intracellular cAMP (Stierl M et al. 2011). In turn, the cAMP opens a cAMP-gated ion channel. This produces slow, whole-cell Ca2+ transients and voltage changes. To increase the speed of these transients, we add the inwardly rectifying potassium channel Kir2.1, the bacterial voltage-gated sodium channel NAVROSD, and Connexin-43. The result is a highly reproducible, medium-throughput, live cell system that can be used to screen voltage and Ca2+ sensors.

Indexed as

Adenylyl CyclasesBiosensing TechniquesCalciumConnexin 43Cyclic AMPHEK293 CellsHumansPotassium Channels, Inwardly RectifyingSignal TransductionAdenylyl CyclasesCalciumConnexin 43Cyclic AMPKir2.1 channelPotassium Channels, Inwardly Rectifying

Identifiers

PMID33378334
PMCPMC7773186
OpenAlexW3114756678

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.